Cidara therapeutics, inc. (CDTX)
CashFlow / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14
Operating activities:
Operating activities:
Net Income (Loss) Attributable to Parent

-14,539

-14,023

3,039

-13,547

-16,561

-12,342

-13,619

-16,306

-16,749

-13,428

-12,257

-16,645

-13,398

-14,394

-12,227

-11,755

-9,789

-9,868

-9,174

-6,414

-6,737

-4,649

-3,319

-3,219

-707

Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization

71

49

81

84

86

111

137

136

139

139

144

186

198

185

178

190

179

172

100

98

91

-

-

-

-

Stock-based compensation

1,246

1,023

1,509

1,257

1,284

1,364

1,285

1,600

1,461

1,508

1,554

1,601

1,051

1,090

1,312

1,109

833

788

766

840

639

175

49

6

2

Amortization of debt issuance costs and debt discount

-

-

-

-

-

-

-

-

-

-

20

19

19

-

-

-

-

-

-

-

-

-

-

-

-

Non-cash interest expense

1

6

7

8

7

43

-38

23

15

-

-

-

-

-

-

-

0

-

-

-

-

0

0

31

35

Amortization of discount or premium on short-term investments

-

-

-

-

-

5

17

-17

-36

-12

-2

8

39

49

47

43

37

-

-

-

-

-

-

-

-

Change in fair value of convertible notes payable

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

-80

-103

Amortization of debt issuance costs

0

1

3

2

2

-34

47

-5

5

-

-

-

-

-

-

-

-

5

6

5

6

0

0

13

10

Operating lease right-of-use assets and liabilities, net

-12

-6

-7

-12

72

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Deferred rent

-

-

-

-

-

-19

-20

-1

10

10

9

5

5

4

5

0

-1

0

-61

3

4

-

-

-

-

Change in fair value of contingent forward purchase obligations

0

0

0

681

-270

4,075

888

-1,112

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Changes in assets and liabilities:
Accounts receivable, prepaid expenses, other current assets, and other assets

1,328

-

-

-

301

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Accounts payable and accrued liabilities

379

-1,054

1,627

-126

-1,231

908

606

-2,122

549

1,827

-3,321

2,935

-799

306

2,532

774

-1,699

1,605

798

-298

38

1,099

-116

607

156

Accrued compensation and benefits

-1,422

925

406

687

-774

434

442

596

-650

825

276

481

-1,129

688

637

654

-219

352

357

382

-41

163

225

11

15

Prepaid expenses and other current assets

-

-

-

-

-

-1,441

931

1,203

-482

529

155

381

416

-430

67

284

155

-236

203

476

44

12

109

59

24

Deferred revenue

476

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net cash used in operating activities

-15,128

-

-

-

-17,146

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Investing activities:
Net cash used in operating activities

-

-

-

-

-

-

-

-15,533

-14,722

-

-

-12,032

-14,518

-

-7,687

-9,472

-10,886

-6,738

-7,303

-5,866

-6,052

-3,172

-3,224

-904

-410

Investing activities:
Purchases of short-term investments

-

-

-

-

-

0

0

8,745

5,803

9,643

9,880

0

0

0

21,835

37,823

9,959

-

-

-

-

-

-

-

-

Maturities of short-term investments

-

-

-

-

-

4,500

9,770

8,471

6,285

5,000

0

7,900

11,400

35,500

25,000

25,000

10,000

-

-

-

-

-

-

-

-

Purchases of property and equipment

36

0

0

26

9

40

82

24

31

140

-9

59

116

114

70

163

54

462

551

126

31

146

167

677

1

Net cash used in investing activities

-36

-

-

-

-9

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Financing activities:
Net cash (used in) provided by investing activities

-

-

-

-

-

-

-

-298

451

-

-

7,841

11,284

-

3,095

-12,986

-13

4,558

-50,489

-126

-31

-146

-167

-677

-1

Financing activities:
Proceeds from issuance of common and preferred stock pursuant to rights offering, net of issuance costs

29,186

0

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from issuance of common stock, net of issuance costs

19

-

-

0

0

-

-

0

6,440

-

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from issuance of convertible notes payable, net of offering costs

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

930

Deferred initial public offering costs

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

626

-

-

-

-

Proceeds from exercise of stock options

5

7

0

0

0

0

165

11

28

76

3

5

144

455

4

25

41

271

0

0

116

739

-8

8

10

Repurchase of unvested restricted stock

-

-

-

-

-

-

-

-

-

0

0

0

79

0

0

0

0

-

-

-

-

-

-

-

-

Net cash provided by financing activities

29,210

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net cash provided by financing activities

-

-

-

-

-

-

-

51,775

6,468

-

-

5

65

-

-57

25

41

271

-38

70,169

41,411

546

-48

29,874

940

Net increase (decrease) in cash, cash equivalents, and restricted cash

14,046

-13,556

29,251

-12,834

-17,155

-9,218

-5,174

35,944

-7,803

-

-

-

-3,169

-

-

-

-

-

-

-

-

-

-

-

-

Net increase (decrease) in cash and cash equivalents

-

-

-

-

-

-

-

-

-

-

-

-

-

60,745

-4,649

-22,433

-10,858

-1,909

-57,830

64,177

35,328

-2,772

-3,439

28,293

529

Supplemental disclosure of cash flows:
Interest paid

139

144

157

160

155

150

150

145

137

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Interest paid

-

-

-

-

-

-

-

-

-

-

-

127

118

-

0

0

0

-

-

-

-

-

-

-

-

Non-cash investing activities:
Right-of-use asset obtained in exchange for lease liability

0

-

0

0

2,295

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Property and equipment acquired but not yet paid

-

-

-

-

-

-

-

-

-

-

-

-

-

-17

-32

-4

74

-

-

-

22

-

-

-

-

Non-cash financing activities:
Deferred initial public offering costs

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-477

490

-

-

-

-

Vesting of early exercised stock options

-

-

-

-

-

0

3

9

9

9

10

9

16

31

31

60

75

-

-

-

-

-

-

-

-

Deferred financing costs incurred but not yet paid

-

-

-

-

-

-

-

-

133

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-